Literature DB >> 4027993

Prognostic factors in patients with advanced stage prostate cancer.

L J Emrich, R L Priore, G P Murphy, M F Brady.   

Abstract

The relationships of 13 potential prognostic factors to objective response to treatment and survival time were investigated, using data gathered on 1,020 patients with advanced stage prostate cancer who have participated in the clinical trials of the National Prostatic Cancer Project. Multivariate statistical analyses revealed that previous hormone response status, analgesics, pain, elevated acid phosphatase, and anemia were the important, independent prognostic factors for objective response to treatment. For survival time, the significant prognostic factors were previous hormone response status, anorexia, elevated acid phosphatase, pain, elevated alkaline phosphatase, obstructive symptoms, tumor grade, performance status, anemia, and age at diagnosis. It is recommended that future treatment protocols for advanced stage prostate cancer take into account heterogeneity of the treatment groups with respect to these factors, either through the design of the protocol, or at the time of analysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027993

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  A systematic review of the impact of pain on overall survival in patients with cancer.

Authors:  Dylan Zylla; Grant Steele; Pankaj Gupta
Journal:  Support Care Cancer       Date:  2017-02-11       Impact factor: 3.603

2.  Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer.

Authors:  T Ueda; T Ichikawa; J Tamaru; A Mikata; K Akakura; S Akimoto; T Imai; O Yoshie; T Shiraishi; R Yatani; H Ito; J Shimazaki
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

3.  Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?

Authors:  Giuseppe Colloca; Pasquale Colloca
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

4.  Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.

Authors:  Philipp Nuhn; Ajay M Vaghasia; Jatinder Goyal; Xian C Zhou; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
Journal:  BJU Int       Date:  2014-02-14       Impact factor: 5.588

5.  Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Authors:  Rubén Algarra; Mateo Hevia; Antonio Tienza; Imanol Merino; José María Velis; Javier Zudaire; José Enrique Robles; Ignacio Pascual
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

6.  The value of prognostic factors in prostatic cancer.

Authors:  J Schubert; S Kowalik
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 7.  Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.

Authors:  M Noguchi; H Kikuchi; M Ishibashi; S Noda
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

8.  Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy.

Authors:  Chien-Hua Chen; Ju-Ton Hsieh; Kuo-How Huang; Yeong-Shiau Pu; Hong-Chiang Chang
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

9.  Radium-223 and concomitant therapies: prospects and prudence.

Authors:  Oladapo Yeku; Susan F Slovin
Journal:  Transl Androl Urol       Date:  2016-12

10.  Influence of nonregional lymph node metastasis as a prognostic factor in metastatic prostate cancer patients.

Authors:  Seok Cho; Sung Gu Kang; Bum Sik Tae; Jun Cheon
Journal:  Korean J Urol       Date:  2012-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.